A Study of Lu AF82422 in Participants With Multiple System Atrophy (NCT05104476)

🧪 Interventions in This Study

• Lu AF82422 (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (19 Sites)

• The Parkinsons and Movement Disorder Institute — Fountain Valley, California
• University of California - San Diego — La Jolla, California
• University of California, San Francisco Neurosciences Clinical Research Unit — San Francisco, California
• CenExel Rocky Mountain Clinical Research, LLC — Englewood, Colorado
• Parkinson's Disease And Movement Disorder Center Of Boca Raton — Boca Raton, Florida
• University of Florida Norman Fixel Institute for Neurological Diseases — Gainesville, Florida
• Rush University Medical Center, Rush University Cancer Center — Chicago, Illinois
• Endeavor Health - Glenbrook Hospital — Glenview, Illinois
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Mayo Clinic — Rochester, Minnesota
• University Nebraska Medical Center — Omaha, Nebraska
• NYU Langone Health Medical Center — New York, New York
• Columbia University Medical Center - The Neurological Institute of New York — New York, New York
• Penn State Milton S. Hershey Medical Center - Penn State Hershey Neuroscience Institute (PSHNI) — Hershey, Pennsylvania
• University of Pennsylvania — Philadelphia, Pennsylvania
• University Of Pittsburgh — Pittsburgh, Pennsylvania
• Fujita Health University Hospital — Toyoake, Aichi-ken
• Gifu University Hospital — Gifu, Gifu
• National Hospital Organization Sendai Nishitaga Hospital — Sendai, Miyagi

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple System Atrophy

• Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy — Rochester, Minnesota
• A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy — Los Angeles, California
• GDNF Gene Therapy for Multiple System Atrophy — Irvine, California
• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Scottsdale, Arizona
• Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic — Nashville, Tennessee

Explore by condition: All Multiple System Atrophy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.